Friday, February 15, 2008

Another Drug-Company Outrage

Sen. McCain thinks they chisel the taxpayers, Sens. Obama and Clinton are sure they have too much influence in Washington, and now a member of Big Pharma goes and does this:

CNBC’s Mike Huckman reported on a study just released in the New England Journal of Medicine that found that Rituxan, a joint-venture between Genentech and Biodec intended for use on rheumatoid arthritis and non-Hodgkin’s lymphoma, is also useful in treating M.S. According to the study, patients using Rituxan saw a 58% decrease in M.S. flare-ups and a 91% drop in brain legions after just two infusions of the drug.

The NEJM, by the way, used to be edited by Marcia Angell, a major drug-company critic. Don't expect any telegenic Congressional hearings on this outrage any time soon, nor any critical reflection from Congress on how going after "the drug companies" might affect the incentive to engage in activity such as this. Thinking about the health-care system twenty years from now, as opposed to thinking about the next election, just ain't part of their job description.


Post a Comment

<< Home